Simplify Logo

Full-Time

Director – Analytical Development

CMC

Posted on 4/30/2024

Verve Therapeutics

Verve Therapeutics

201-500 employees

Developing gene editing therapies for heart disease

Hardware
Biotechnology
Healthcare

Expert

Boston, MA, USA

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • BS in a life sciences field, MS or PhD in analytical chemistry with 10+ years of analytical development experience
  • Prior laboratory operations and management experience leading a team of scientists and associates for analytical development in a clinical stage biotech environment
  • Experience with planning and executing product and process development studies such as forced degradation, comparability assessments, stability, etc.
  • Demonstrated competency in operating HPLC/UPLC/LC-MS instrumentation
  • Hands-on experience analyzing DNA/RNA by IP-RP, IEX, LC-fluor and multi-modal LC techniques
  • Direct experience analyzing LNPs and RNA by biophysical techniques such as DSC, CGE, UV thermal analysis, DLS, MALS, Ribogreen, etc.
  • Conceptual understanding of solid phase oligonucleotide synthesis and purification strategies
Responsibilities
  • Lead a team of scientists and research associates working on mRNA, gRNA and LNP assays focused on biophysical methodologies
  • Provide technical expertise for the structural characterization of gRNAs, mRNAs and lipid nanoparticle (LNP) complexes
  • Partner across the Analytical Development team and cross-functionally to lead, plan, and execute complex characterization studies
  • Develop and implement methods intended for a variety of purposes, including release and stability testing, product characterization, and high throughput analysis
  • Serve as analytical lead for CMC project teams
  • Oversee troubleshooting, tech transfer, and phase-appropriate GMP validation of analytical methods
  • Author and review technical reports and regulatory submissions
  • Provide guidance and support to team members, promoting their professional growth and development
  • Effectively manage multiple projects to ensure timely delivery
  • Foster a culture of lab safety, data integrity, collaboration, innovation, continuous improvement and accountability within the team

Verve Therapeutics is developing single-course gene editing medicines to address cardiovascular disease, with a focus on precision genetic editing technologies to lower LDL cholesterol and triglyceride levels. Their lead program, VERVE-101, targets heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

Company Stage

IPO

Total Funding

$419.3M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

5%

1 year growth

5%

2 year growth

40%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant financial backing, including a $63 million Series A2 financing and $60 million from Eli Lilly, positions Verve for robust R&D and clinical trial activities.
  • The potential for a 'one-and-done' treatment for cardiovascular diseases could revolutionize the field and offer a high-impact, life-saving solution.
  • Early-stage success and strategic partnerships could lead to lucrative licensing deals and further investment opportunities.

What critics are saying

  • The clinical-stage nature of Verve's therapies means they are still years away from potential market approval, posing a long-term risk.
  • The recent stock price drop following a public offering indicates market volatility and potential investor uncertainty.

What makes Verve Therapeutics unique

  • Verve Therapeutics focuses on gene-editing therapies specifically for cardiovascular diseases, setting it apart from other CRISPR-based companies that target a broader range of conditions.
  • Their 'one-and-done' gene-editing approach aims to provide a single, curative treatment, which is a significant advantage over traditional, ongoing therapies.
  • Partnerships with major pharmaceutical companies like Eli Lilly enhance their credibility and provide substantial financial and research support.
INACTIVE